Historical Valuation
Silence Therapeutics PLC (SLN) is now in the Fair zone, suggesting that its current forward PS ratio of 21.42 is considered Fairly compared with the five-year average of -14.19. The fair price of Silence Therapeutics PLC (SLN) is between 0.90 to 11.96 according to relative valuation methord.
Relative Value
Fair Zone
0.90-11.96
Current Price：5.50
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Silence Therapeutics PLC (SLN) has a current Price-to-Book (P/B) ratio of 3.92. Compared to its 3-year average P/B ratio of 10.61 , the current P/B ratio is approximately -63.03% higher. Relative to its 5-year average P/B ratio of 16.61, the current P/B ratio is about -76.38% higher. Silence Therapeutics PLC (SLN) has a Forward Free Cash Flow (FCF) yield of approximately -24.99%. Compared to its 3-year average FCF yield of -18.56%, the current FCF yield is approximately 34.60% lower. Relative to its 5-year average FCF yield of -12.96% , the current FCF yield is about 92.77% lower.
P/B
Median3y
10.61
Median5y
16.61
FCF Yield
Median3y
-18.56
Median5y
-12.96
Competitors Valuation Multiple
AI Analysis for SLN
The average P/S ratio for SLN competitors is 15.00, providing a benchmark for relative valuation. Silence Therapeutics PLC Corp (SLN.O) exhibits a P/S ratio of 21.42, which is 42.83% above the industry average. Given its robust revenue growth of -89.29%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SLN
1Y
3Y
5Y
Market capitalization of SLN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SLN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SLN currently overvalued or undervalued?
Silence Therapeutics PLC (SLN) is now in the Fair zone, suggesting that its current forward PS ratio of 21.42 is considered Fairly compared with the five-year average of -14.19. The fair price of Silence Therapeutics PLC (SLN) is between 0.90 to 11.96 according to relative valuation methord.
What is Silence Therapeutics PLC (SLN) fair value?
SLN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Silence Therapeutics PLC (SLN) is between 0.90 to 11.96 according to relative valuation methord.
How does SLN's valuation metrics compare to the industry average?
The average P/S ratio for SLN's competitors is 15.00, providing a benchmark for relative valuation. Silence Therapeutics PLC Corp (SLN) exhibits a P/S ratio of 21.42, which is 42.83% above the industry average. Given its robust revenue growth of -89.29%, this premium appears unsustainable.
What is the current P/B ratio for Silence Therapeutics PLC (SLN) as of Jan 10 2026?
As of Jan 10 2026, Silence Therapeutics PLC (SLN) has a P/B ratio of 3.92. This indicates that the market values SLN at 3.92 times its book value.
What is the current FCF Yield for Silence Therapeutics PLC (SLN) as of Jan 10 2026?
As of Jan 10 2026, Silence Therapeutics PLC (SLN) has a FCF Yield of -24.99%. This means that for every dollar of Silence Therapeutics PLC’s market capitalization, the company generates -24.99 cents in free cash flow.
What is the current Forward P/E ratio for Silence Therapeutics PLC (SLN) as of Jan 10 2026?
As of Jan 10 2026, Silence Therapeutics PLC (SLN) has a Forward P/E ratio of -6.48. This means the market is willing to pay $-6.48 for every dollar of Silence Therapeutics PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Silence Therapeutics PLC (SLN) as of Jan 10 2026?
As of Jan 10 2026, Silence Therapeutics PLC (SLN) has a Forward P/S ratio of 21.42. This means the market is valuing SLN at $21.42 for every dollar of expected revenue over the next 12 months.